Pfizer and the French-Swiss firm Valneva say trials have shown a 70% efficacy rate in people aged five and above.

Previously, a vaccine called LYMErix was administered to prevent Lyme disease. It was approved by the FDA in 1998, but ...

Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) ...

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for ...

EU officials have agreed to study an experimental vaccine against Lyme disease, the world's most common tick-borne illness, ...

After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU, and the EMA has started its review. The six-valent ...

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary ...

The mouthparts of an adult female blacklegged tick, also known as a deer tick. The outer protrusions are used to secure a ...

Respiratory syncytial virus, or RSV, is dangerous for certain adults and babies. Here is the latest information on ...

EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine: New York Monday, August 17, 2026, 11:00 Hrs [IST ...

The Boise and West Ada school districts began classes Aug. 12, which is the most recent day for which the wastewater data is ...

RSV poses a health threat to some older adults, prompting CDC's call for vaccination and Medicare's assurance of coverage of ...